NVIDIA, Anthropic and Roche Back Basecamp Research's $140m Series C

Basecamp Research has closed an oversubscribed US$140m Series C round, drawing capital from NVIDIA, Anthropic and senior pharmaceutical executives in one of the clearest signals yet of investor appetite for AI-designed therapeutics.

Venture capital firm S32 led the financing, which counts roughly US$3.5bn in assets under management and was founded in 2017 by Bill Maris, the former CEO of Google Ventures. Andy Conrad, S32 General Partner and former CEO of Google's Verily, joins Basecamp's board. The firm raised US$517m for its sixth flagship fund earlier in 2026.

Anthropic participated through its Anthology Fund. The round also included Catalio Capital Management, European Tech Collective, Firebrand River Capital, ATO Innovation Fund, Redalpine, The Rockefeller Foundation, Singular and True Ventures. Sovereign AI, the UK's state-backed, AI-focused venture capital fund launched in April 2026, also invested.

The deal pulled in individual cheques from senior leaders across pharma, biotech and global industry. Among them is André Hoffmann, Vice-Chairman of Roche, who frames the bet in historical terms.

"The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey," Hoffmann says. "Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate."

Scaling EDEN and in vivo cell therapy

The funding has two stated priorities: training the next generation of EDEN models and advancing Basecamp's pipeline of AI-designed therapeutics toward clinical development.

London-headquartered Basecamp Research applies its biological foundation model, EDEN, to in vivo cell therapy. The goal is to reprogramme a patient's cells directly inside the body. The stakes are economic as much as scientific: existing cell therapies can cost hundreds of thousands of dollars per patient because they are complex and expensive to manufacture.

Basecamp combines EDEN's ability to design long, complex DNA sequences with large serine recombinases, which integrate those sequences precisely into the genome. According to the company, the approach could enable more sophisticated, personalised cell therapies while simplifying delivery and manufacturing. Potential applications span cancer, autoimmune disease and other conditions.

Emma Bolton, VP of Global Research at Basecamp, set out the plan on LinkedIn after the announcement.

"With this funding, we can focus on our goal of training our EDEN models on evolutionary data from our global biodiversity partnerships and clinical data from our in-house Science team," Bolton writes, as the company leverages AI to "accelerate the development of curative medicines for genetic disease."

The Trillion Gene Atlas

EDEN's training rests on what Basecamp describes as the world's largest proprietary biological AI training dataset: the Trillion Gene Atlas. The dataset was built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, drawing on biological data collected through access and benefit-sharing partnerships spanning more than 30 countries and all seven continents.

The EDEN models use that data to identify patterns across a vast range of previously unseen biology. Rather than targeting a single scientific application, the models build a broader understanding of how DNA functions across different forms of life. That foundation lets EDEN generate potential therapeutic candidates from information about a disease.

Basecamp has already tested the approach through its collaboration with Anthropic on Claude Science. The models can also support the design of cell and gene therapies, enzymes and peptides.

The breadth of the cap table — a sovereign AI fund, two of the biggest names in frontier AI computing and the vice-chairman of one of the world's largest drugmakers — signals that AI-designed therapeutics have moved from speculative science to a mainstream institutional bet.